Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 207 participants.
Also called NCT03812328
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 207 participants
- Sponsor
- Tetherex Pharmaceuticals Corporation
- Registry
-
NCT03812328 -
2018-003122-88
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Bulgaria, Latvia, Lithuania, Poland, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT03812328. Randomized; single masking; primary purpose prevention. Start 2019-02-20 (actual); primary completion 2019-10-01 (actual). Results posted on 2020-11-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement
- Acronym
- COURSE
- Condition
- Venous Thromboembolism
- Intervention (Drug)
- SelK2
- Intervention (Biological)
- Enoxaparin
- Lead sponsor
- Tetherex Pharmaceuticals Corporation
Record details
- Record id
cardio:ct-nct03812328- Content hash
7c173624a16f7917515f21ef6c64cda432112ca7be48194de6969f0a9218ab9a